Yadav, N.; Tripathi, A.K.; Parveen, A.; Parveen, S.; Banerjee, M.
Correction: Yadav et al. PLGA-Quercetin Nano-Formulation Inhibits Cancer Progression via Mitochondrial Dependent Caspase-3,7 and Independent FoxO1 Activation with Concomitant PI3K/AKT Suppression. Pharmaceutics 2022, 14, 1326. Pharmaceutics 2024, 16, 124.
https://doi.org/10.3390/pharmaceutics16010124
AMA Style
Yadav N, Tripathi AK, Parveen A, Parveen S, Banerjee M.
Correction: Yadav et al. PLGA-Quercetin Nano-Formulation Inhibits Cancer Progression via Mitochondrial Dependent Caspase-3,7 and Independent FoxO1 Activation with Concomitant PI3K/AKT Suppression. Pharmaceutics 2022, 14, 1326. Pharmaceutics. 2024; 16(1):124.
https://doi.org/10.3390/pharmaceutics16010124
Chicago/Turabian Style
Yadav, Neera, Amit Kumar Tripathi, Amna Parveen, Shama Parveen, and Monisha Banerjee.
2024. "Correction: Yadav et al. PLGA-Quercetin Nano-Formulation Inhibits Cancer Progression via Mitochondrial Dependent Caspase-3,7 and Independent FoxO1 Activation with Concomitant PI3K/AKT Suppression. Pharmaceutics 2022, 14, 1326" Pharmaceutics 16, no. 1: 124.
https://doi.org/10.3390/pharmaceutics16010124
APA Style
Yadav, N., Tripathi, A. K., Parveen, A., Parveen, S., & Banerjee, M.
(2024). Correction: Yadav et al. PLGA-Quercetin Nano-Formulation Inhibits Cancer Progression via Mitochondrial Dependent Caspase-3,7 and Independent FoxO1 Activation with Concomitant PI3K/AKT Suppression. Pharmaceutics 2022, 14, 1326. Pharmaceutics, 16(1), 124.
https://doi.org/10.3390/pharmaceutics16010124
